Find a Trial

Featured Trials

  1. ALOFT-IPF
    A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis (IM027-068).
    Trial Category: Featured Trial Age Group: Over 40 years Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Participant Type: Patient Trial Phase: Phase 3 Trial Location: NSW QLD VIC WA Trial Status: Recruiting Trial Type: Interventional
  2. ALOFT-PPF
    A Multiicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis (IM027-1015).
    Trial Category: Featured Trial Age Group: Over 21 years Trial Disease Type: Progressive Pulmonary Fibrosis Trial Participant Type: Patient Trial Phase: Phase 3 Trial Location: NSW QLD VIC WA Trial Status: Recruiting Trial Type: Interventional
  3. BI 1839100 Study
    A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough.
    Trial Category: Featured Trial Age Group: Over 18 years Over 40 years Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Progressive Pulmonary Fibrosis Trial Participant Type: Carer Trial Phase: Phase 2 Trial Location: ACT New Zealand NSW TAS VIC WA Trial Status: Recruiting Trial Type: Interventional

All Trials and Search Filter

Location:
Participant Type:
Age:
Disease:
Type:
Status:
Phase:
  1. ALOFT-IPF

    A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis (IM027-068).

  2. ALOFT-PPF

    A Multiicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis (IM027-1015).

  3. BI 1839100 Study

    A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough.

  4. ASPIRE IPF Study

    A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid Over 52 Weeks in People with Idiopathic Pulmonary Fibrosis.

  5. BI 1819479 Study

    This study is to find out whether a medicine called BI 1819479 helps people with Idiopathic Pulmonary Fibrosis (IPF).

  6. CORAL

    Cough Reduction in IPF with nalbuphine ER.

  7. Avalyn AP01 MIST

    A Study Evaluating the Safety and Efficacy of AP01 in Participants with Progressive Pulmonary Fibrosis (PPF).

  8. REBUILD-SM Trial

    A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (REBUILD-SM trial).

  9. SNDX-6352-0506

    A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF).

  10. GRIPF

    Genetic Research in Idiopathic Pulmonary Fibrosis.

  11. BEACON-IPF

    A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF).

  12. The TELO-SCOPE Study

    Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis.

  13. SHIELD

    The SHIELD Whole Lung Lavage Observational Cohort Study.

  14. SINFONIA

    A clinical trial examining the benefits of SingINg For breathing in COPD aNd ILD pAtients.

  15. Novartis LTP001

    A participant and investigator-blinded, randomized, placebo-controlled, multicentre, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis.

Clinical trials listed on this website are limited to PACT endorsed studies. For a comprehensive list of all pulmonary fibrosis clinical trials please go to Australian Clinical Trials (australianclinicaltrials.gov.au).